Sarah Graner, MD
Neurology · Honolulu, HINPI 1053671552
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,911 of the $9,738 with a category attached, or 71.0%. It is spread thinly across 35 manufacturers, the largest accounting for just 23.7%. Reporting peaked in 2021 at $3,549 and has fallen 96.1% since, to $140 in 2025.
Across 289 payments — averaging $33.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Abbott$1K
- AbbVie$1K
- UCB, Inc.$691
- Eisai Inc.$503
- Amgen$437
- plus $3K from 29 others
What the payments were for
- Speaking & faculty fees$440%
- Travel & lodging$2,78329%
- Food & beverage$6,91171%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 17 | $2,311 |
| Abbott | 11 | $1,500 |
| AbbVie(2 entities) | 63 | $1,246 |
| UCB, Inc. | 25 | $691 |
| Eisai Inc. | 18 | $503 |
| Amgen | 15 | $437 |
| Teva Pharmaceuticals USA, Inc. | 24 | $433 |
| Biogen | 18 | $356 |
| Neurocrine Biosciences, Inc. | 11 | $305 |
| AstraZeneca | 8 | $209 |
| Neurelis, Inc. | 11 | $191 |
| Lundbeck LLC | 9 | $180 |
| Upsher-smith Laboratories LLC | 9 | $175 |
| Merz North America, Inc. | 3 | $163 |
| Kyowa Kirin, Inc. | 6 | $116 |
| Novartis | 5 | $105 |
| Lilly USA, LLC | 3 | $100 |
| Jazz Pharmaceuticals Inc. | 4 | $68 |
| Adamas Pharmaceuticals, Inc. | 3 | $66 |
| Harmony Biosciences LLC | 2 | $65 |
| Biohaven Pharmaceuticals, Inc. | 3 | $59 |
| Akcea Therapeutics, Inc. | 2 | $56 |
| Acorda Therapeutics, Inc | 2 | $44 |
| CSL Behring | 2 | $43 |
| Merz Pharmaceuticals, LLC | 1 | $43 |
| Tanabe Pharma America, Inc. | 2 | $38 |
| EMD Serono, Inc. | 2 | $36 |
| Amneal Pharmaceuticals LLC | 2 | $35 |
| Catalyst Pharmaceuticals, Inc. | 1 | $32 |
| SK Life Science, Inc. | 2 | $32 |
| Grifols USA, LLC | 1 | $27 |
| Alnylam Pharmaceuticals Inc. | 1 | $21 |
| Livanova USA, Inc. | 1 | $18 |
| Avanir Pharmaceuticals, Inc. | 1 | $18 |
| Arbor Pharmaceuticals, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ACTIVA$1,808
- Proclaim Family of SCS IPGs$1,093
How this compares
$9,738 in reported general payments places this provider in the 80th percentile of 54 neurology providers in Hawaii.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RytaryCarbidopa/Levodopa | 49 | $192,790 |
| IngrezzaValbenazine Tosylate | 13 | $117,500 |
| InbrijaLevodopa | 13 | $27,737 |
| UbrelvyUbrogepant | 36 | $26,325 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 371 | $21,004 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 37 | $19,898 |
| QuliptaAtogepant | 14 | $12,338 |
| Droxidopa | 16 | $9,447 |
| Gabapentin | 192 | $4,527 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 109 | $4,359 |
| Carbamazepine ErCarbamazepine | 26 | $3,184 |
| Propranolol Hcl | 77 | $3,072 |
| AmantadineAmantadine Hcl | 111 | $3,028 |
| Levetiracetam | 87 | $2,743 |
| Primidone | 54 | $2,378 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide | $35 | $194,37967 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $305 | $117,50013 claims |
| AbbVieUbrelvy, Qulipta | $1,246 | $38,66350 claims |
| Acorda Therapeutics, IncInbrija | $44 | $27,73713 claims |
| Upsher-smith Laboratories LLCTopiramate | $175 | $1,36179 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 54 neurology providers in Hawaii.
Other neurology in Honolulu
- Leo MaherHonolulu$382K
- Leah RidgeHonolulu$47K
- Melvin YeeHonolulu$32K
- Kevin KimataHonolulu$24K
- Terry ShimamotoHonolulu$24K
- Michael RussoHonolulu$20K
- Kore LiowHonolulu$15K
- Fay GaoHonolulu$13K
- Jeffrey LiuHonolulu$8K
- Monique CanonicoHonolulu$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.